Your browser doesn't support javascript.
loading
Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration.
Wisse, L E M; Das, S R; Davatzikos, C; Dickerson, B C; Xie, S X; Yushkevich, P A; Wolk, D A.
Afiliación
  • Wisse LEM; Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, 3700 Hamilton Walk, Philadelphia, PA 19104, USA. Electronic address: Laura.Wisse@uphs.upenn.edu.
  • Das SR; Penn Memory Center, Department of Neurology, 3700 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Davatzikos C; Center for Biomedical Image Computing and Analytics, 3700 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Dickerson BC; Department of Psychiatry and Neurology Services, Massachusetts General Hospital, Harvard Medical School, Building 149 13th Street, Charlestown, MA 02129, USA.
  • Xie SX; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
  • Yushkevich PA; Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, 3700 Hamilton Walk, Philadelphia, PA 19104, USA.
  • Wolk DA; Penn Memory Center, Department of Neurology, 3700 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104, USA.
Neuroimage Clin ; 18: 407-412, 2018.
Article en En | MEDLINE | ID: mdl-29487798
ABSTRACT

Introduction:

Suspected non-Alzheimer's pathophysiology (SNAP) is a biomarker driven designation that represents a heterogeneous group in terms of etiology and prognosis. SNAP has only been identified by cross-sectional neurodegeneration measures, whereas longitudinal measures might better reflect "active" neurodegeneration and might be more tightly linked to prognosis. We compare neurodegeneration defined by cross-sectional 'hippocampal volume' only (SNAP/L-) versus both cross-sectional and longitudinal 'hippocampal atrophy rate' (SNAP/L+) and investigate how these definitions impact prevalence and the clinical and biomarker profile of SNAP in Mild Cognitive Impairment (MCI).

Methods:

276 MCI patients from ADNI-GO/2 were designated amyloid "positive" (A+) or "negative" (A-) based on their florbetapir scan and neurodegeneration 'positive' or 'negative' based on cross-sectional hippocampal volume and longitudinal hippocampal atrophy rate.

Results:

74.1% of all SNAP participants defined by the cross-sectional definition of neurodegeneration also met the longitudinal definition of neurodegeneration, whereas 25.9% did not. SNAP/L+ displayed larger white matter hyperintensity volume, a higher conversion rate to dementia over 5 years and a steeper decline on cognitive tasks compared to SNAP/L- and the A- CN group. SNAP/L- had more abnormal values on neuroimaging markers and worse performance on cognitive tasks than the A- CN group, but did not show a difference in dementia conversion rate or longitudinal cognition.

Discussion:

Using a longitudinal definition of neurodegeneration in addition to a cross-sectional one identifies SNAP participants with significant cognitive decline and a worse clinical prognosis for which cerebrovascular disease may be an important driver.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Disfunción Cognitiva / Hipocampo Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: Neuroimage Clin Año: 2018 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Disfunción Cognitiva / Hipocampo Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: Neuroimage Clin Año: 2018 Tipo del documento: Article